Xpert MTB/RIF Testing in a Low Tuberculosis Incidence, High-Resource Setting: Limitations in Accuracy and Clinical Impact
Open Access
- 14 January 2014
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 58 (7), 970-976
- https://doi.org/10.1093/cid/ciu022
Abstract
Background. Xpert MTB/RIF, the first automated molecular test for tuberculosis, is transforming the diagnostic landscape in low-income countries. However, little information is available on its performance in low-incidence, high-resource countries. Methods. We evaluated the accuracy of Xpert in a university hospital tuberculosis clinic in Montreal, Canada, for the detection of pulmonary tuberculosis on induced sputum samples, using mycobacterial cultures as the reference standard. We also assessed the potential reduction in time to diagnosis and treatment initiation. Results. We enrolled 502 consecutive patients who presented for evaluation of possible active tuberculosis (most with abnormal chest radiographs, only 18% symptomatic). Twenty-five subjects were identified to have active tuberculosis by culture. Xpert had a sensitivity of 46% (95% confidence interval [CI], 26%–67%) and specificity of 100% (95% CI, 99%–100%) for detection of Mycobacterium tuberculosis. Sensitivity was 86% (95% CI, 42%–100%) in the 7 subjects with smear-positive results, and 28% (95% CI, 10%–56%) in the remaining subjects with smear-negative, culture-positive results; in this latter group, positive Xpert results were obtained a median 12 days before culture results. Subjects with positive cultures but negative Xpert results had minimal disease: 11 of 13 had no symptoms on presentation, and mean time to positive liquid culture results was 28 days (95% CI, 25–47 days) compared with 14 days (95% CI, 8–21 days) in Xpert/culture-positive cases. Conclusions. Our findings suggest limited potential impact of Xpert testing in high-resource, low-incidence ambulatory settings due to lower sensitivity in the context of less extensive disease, and limited potential to expedite diagnosis beyond what is achieved with the existing, well-performing diagnostic algorithm.Keywords
This publication has 19 references indexed in Scilit:
- Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa.The International Journal of Tuberculosis and Lung Disease, 2013
- Xpert (R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review)Published by Wiley ,2012
- Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care levelSouth African Medical Journal, 2012
- Effectiveness of an Integrated Real-Time PCR Method for Detection of the Mycobacterium tuberculosis Complex in Smear-Negative Extrapulmonary Samples in an Area of Low Tuberculosis PrevalenceJournal of Clinical Microbiology, 2012
- Comparison of the Xpert MTB/RIF Test with an IS 6110 -TaqMan Real-Time PCR Assay for Direct Detection of Mycobacterium tuberculosis in Respiratory and Nonrespiratory SpecimensJournal of Clinical Microbiology, 2011
- Containment of Bioaerosol Infection Risk by the Xpert MTB/RIF Assay and Its Applicability to Point-of-Care SettingsJournal of Clinical Microbiology, 2010
- Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literatureBMC Infectious Diseases, 2009
- Tuberculosis Transmission by Patients with Smear‐Negative Pulmonary Tuberculosis in a Large Cohort in The NetherlandsClinical Infectious Diseases, 2008
- A systematic review of delay in the diagnosis and treatment of tuberculosisBMC Public Health, 2008
- Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilliThe Lancet, 1999